| 8.25 -0.18 (-2.14%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.58 | 1-year : | 14.59 |
| Resists | First : | 10.77 | Second : | 12.5 |
| Pivot price | 9.11 |
|||
| Supports | First : | 7.97 | Second : | 6.63 |
| MAs | MA(5) : | 8.27  |
MA(20) : | 9.64 |
| MA(100) : | 11.14 |
MA(250) : | 0 | |
| MACD | MACD : | -1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 7.3 |
| RSI | RSI(14): 27.5 |
|||
| 52-week | High : | 14.93 | Low : | 3.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ORIC ] has closed above bottom band by 26.9%. Bollinger Bands are 56.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.48 - 8.52 | 8.52 - 8.56 |
| Low: | 8.05 - 8.1 | 8.1 - 8.15 |
| Close: | 8.17 - 8.26 | 8.26 - 8.33 |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Fri, 26 Dec 2025
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - MSN
Mon, 22 Dec 2025
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wed, 17 Dec 2025
Dominic Piscitelli Sells 10,720 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
Wed, 17 Dec 2025
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 7.5% - Here's What Happened - MarketBeat
Sat, 13 Dec 2025
Oric Pharmaceuticals, Inc. $ORIC Shares Sold by EcoR1 Capital LLC - MarketBeat
Fri, 05 Dec 2025
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 6.7 (%) |
| Held by Institutions | 107.2 (%) |
| Shares Short | 17,570 (K) |
| Shares Short P.Month | 15,490 (K) |
| EPS | -1.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.3 % |
| Return on Equity (ttm) | -39.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -117 (M) |
| Levered Free Cash Flow | -71 (M) |
| PE Ratio | -4.83 |
| PEG Ratio | 0 |
| Price to Book value | 1.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|